The latest news from academia, regulators
research labs and other things of interest
Posted: December 18, 2008
Living Cell Technologies Announces Collaboration with Centocor on Encapsulation Technology
(Nanowerk News) Living Cell Technologies Limited today announced that the Company has commenced a research agreement with Centocor Research & Development, Inc. (Centocor). Through this agreement, Centocor will have access to LCT’s proprietary encapsulation technology.
LCT is a world leader in the encapsulation of living cells for research and therapeutic purposes. The alginate capsules consist of three layers with nano scale pores, designed to prevent the host’s immune system from detecting the foreign cells while at the same time allowing nutrients to reach the cells and cell secretions to exit, ensuring long term survival.
LCT has patents pending worldwide on the selection of materials and techniques for placing cells in biocapsules.
Chief Operating Officer of LCT, Dr Paul Tan said, “LCT’s encapsulation technology is a critical factor for the effectiveness of DIABECELL®. We have always known that this technology has much wider application and value. The arrangement with Centocor has the potential for ongoing collaboration and future licensing opportunities.”
About Living Cell Technologies
Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a bio-certified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients having type 1 diabetes, the Company implants micro-encapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. LCT entered clinical trials for its diabetes product in 2007.
The Company is developing treatments for Huntington’s disease and other neurological disorders that involve implantation of micro-encapsulated choroid plexus cells to deliver beneficial proteins and neurotrophic factors to the brain. LCT’s technology has the potential for allowing healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. LCT also is developing medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.